Navigation Links
Precancerous Blood Donors Do Not Pass on the Disease

Dont worry yourselves to death even if those who have donated blood for you might have developed cancer since .

There is no evidence that recipients of blood from donors with undiagnosed cancer are any more or less likely to develop cancer than recipients given blood from non-cancer donors, a study of more than 350,000 blood transfusion recipients shows.

Researchers say the findings are reassuring and a major advancement in the understanding of long-term transfusion-related risks.

"Continuous attention to transfusion safety has reduced the risk of transfusion-transmitted disease to a current record low," writes researcher Gustaf Edgren of the Karolinska Institutet in Stockholm, Sweden, and colleagues.

Although most infections and complications have been relatively easy to identify, the possible transmission of chronic diseases with unknown causes has been far more difficult to address, they write.

The study analyzed data gathered between 1968 and 2002 from computerized blood bank registers in Denmark and Sweden, including information on 1.13 million blood donors and 1.31 million blood transfusion recipients.

Out of the more than 350,000 recipients included in the final analysis, just over 12,000 (3%) were exposed to blood products from donors who later went on to develop cancer.

The blood transfusion recipients were followed for up to 34 years, and the results showed no increased risk of cancer associated with the exposure.

"Our data provide no evidence that blood transfusions from precancerous blood donors are associated with an increased risk of cancer among recipients compared with transfusions from non-cancerous donors," the researchers conclude.

Thanks to the scope and thoroughness of the study, experts say the results represent an important step forward in evaluating one of the potential long-term risks of blood transfusion. But much mor
'"/>




Page: 1 2

Related medicine news :

1. New Approach to Treating Precancerous Esophagus Condition
2. Recommendations for Treatment of Blood Pressue
3. Blood Cells Capable of Regenerating Liver
4. Blood clots likely in long travel
5. Hemochromatosis Patients Blood is Safe
6. Blood transfusions beneficial after heart attacks
7. Blood Pressure Drug may slow wasting in burn victims
8. Levels Of Blood Proteins May Help Heart Disease Care
9. Blood test may identify ovarian cancer
10. A Blood test for suicide risk?
11. Blood Pressure Drugs maintain muscle strength
Post Your Comments:
(Date:12/2/2008)...Newswire/ -- diaDexus, Inc. today,announced that ...mat of the,PLAC Test for Lp-PLA2. This automated ... a wide range of clinical chemistry analyzers, was...tration (FDA) in December 2007. diaDexus also,ann...st to Europe. , The PLAC Test is the only b...
(Date:12/2/2008)...t a symposium today hosted by Johns,Hopkins Univ...archers presented,the latest research in brain pl...cience into technology to improve lives. Henry Mah...vidence that cognitive intervention developed by,...brain,s ability to,reorganize itself throughout l...
(Date:12/2/2008)...ewswire/ -- Are you unhappy with your smile but ar...ailable? , , The Pennsylvania Dental Associ...ptions exist to improve your smile. Your dentist c... determine a suitable option to help restore your ...tal options. , , , , Tooth whi...
(Date:12/2/2008)...ed for 3.5 percent of high school athletes, injuri... to examine rare injuries and conditions of U.S. h...uries, dental injuries, neck and cervical injuries...t in high morbidity, costly surgeries and treatmen... associated with the highest rate of rare injuries...
Breaking Medicine News(10 mins):Health News:diaDexus Receives CE Mark Certification for the PLAC(R) Test 2Health News:Posit Science Invited to Speak at Johns Hopkins University About Cutting Edge Cognitive Training Interventions 2Health News:Cosmetic Dentistry: A Beautiful Smile Is Not Far Away 2
...riggered by viral cold are common in preschoolers....since the frequency disappears by school age. //Th...r oral steroids at the first sign of an attack. Bu...ive is controversial. The research shows a course...
...be a major improvement for HIV patients in less-de...sess a patient's response to HIV medication.// HIV... This treatment is now becoming available in Afric...etermine the CD4 cell count are needed. A low CD4 ...
...to help acne patients. A new study highlights the ...is is important because this skin disease can lead...b and sometimes even suicide. Doctors from London ...ate facial acne. Thirty-one of the patients receiv...
...is year’s meeting of the American Society of Thera...ment //of external beam radiation may be what it t...ers that have spread to the bone. More than 160 ho... States and Canada were involved in a study of abo...
Other Medicine News:
(Date:12/2/2008)... Horizon Therapeutics, Inc., a,pr...unced that two pivotal,Phase 3 trials evaluating ...1,met all primary endpoints. HZT-501, a novel, p...ing ibuprofen and famotidine, demonstrated a,stat...f non-steroidal,anti-inflammatory drug (NSAID)-in...
(Date:12/1/2008)...ICAGO, Dec. 2 A study h... a new technique for imaging the breast, is not af...nal status, two factors that limit the effectivene...ncer. Results will be presented today at the annua...rica (RSNA). , , "The ability of PEM to de...
(Date:12/1/2008)...RNewswire/ -- S*BIO Pte Ltd today announced the in...a potent and orally-active JAK2 inhibitor, in lead... chronic idiopathic myelofibrosis (CIMF). , ,...nd tolerability of SB1518 in patients with CIMF an...se 1 part of the study will assess the safety prof...
(Date:12/1/2008)... the Prox1 gene is a two-way switch that, if turne...programmed so that they lose their identity and be...MEMPHIS, Tenn., Dec. 1 ...al have discovered that a certain differentiated c...t requires the constant expression of a gene calle...
Breaking Medicine Technology:Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3After Effects 3A Giving Back Is Good for You 19422 1After Effects 3A Giving Back Is Good for You 19422 2Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 5419 1Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 5419 2Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 5419 3Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 5419 4Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 5419 5Targeted therapy plus chemotherapy may pack 1 2 punch against melanoma 19417 1Targeted therapy plus chemotherapy may pack 1 2 punch against melanoma 19417 2AUA 2008 3A Global warming may lead to increase in kidney stones disease 19414 1
...IDGE, Mass.--(BUSINESS WIRE)--Jul 2, 2007 - ViaCel.... Beer, President and,Chief Executive Officer of V...ivities and product pipeline at the C.E. Unterberg...on Tuesday, July,10, 2007 at 3:00 p.m. at the Mand...webcast of the presentation will be available on,t...
...ESTER, Mass., Jun 27, 2007 (PrimeNewswire via COMT...ion (Nasdaq:GNBT), the,leader in drug delivery for...e mouth, announced today that it will be making th...g of the European,Society of Pediatric Endocrinolo...rget="_blank" href=,"http://www.espe2007.org/">www...
Other Medicine Technology:Generex Biotechnology to Make Presentations At 46th Annual Meeting,of the European Society of Pediatric Endocrinology 2Generex Biotechnology to Make Presentations At 46th Annual Meeting,of the European Society of Pediatric Endocrinology 3
... integrated technology and service--mobile,outpati...heartbeat, ECG monitoring, analysis and response, ...y focused on helping physicians diagnose and treat...in diagnosing and treating arrhythmia. Delays can ...
...rmance temperature controlled shaker which accommo...eed and incubation time are fully programmable via...ed on the LCD in real time. Microprocessor-control... provide uniform incubation with less than 0.6 C v...
The iEMS Incubator/Shaker HT is designed for extended temperatures. Thus, the iEMS Incubator/Shaker HT is ideal for applications such as DNA hybridization and primer extension assays. iEMS Incubator/
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -
Medicine Products: